Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia, Myeloid, Acute 6Leukemia 6Burkitt Lymphoma 5Leukemia, Lymphocytic, Chronic, B-Cell 4Myelodysplastic Syndromes 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Leukemia, Prolymphocytic 3Myeloproliferative Disorders 2Leukemia, Plasma Cell 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Congenital Abnormalities 2Tumor Lysis Syndrome 1Sarcoma, Alveolar Soft Part 1Recurrence 1Primary Myelofibrosis 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid 1

Interventions

rasburicase 2Allopurinol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Tumor Lysis Syndrome × Allopurinol × Clear all
NCT01200485 2020-01-31

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

M.D. Anderson Cancer Center

Phase 2 Completed
55 enrolled 11 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Tumor Lysis Syndrome, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡